Douglas Tsao
Stock Analyst at HC Wainwright & Co.
(3.19)
# 1,126
Out of 4,711 analysts
481
Total ratings
42.17%
Success rate
2.5%
Average return
Main Sectors:
Stocks Rated by Douglas Tsao
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRDN Viridian Therapeutics | Reiterates: Buy | $34 | $19.03 | +78.67% | 15 | Dec 17, 2024 | |
| BHVN Biohaven | Reiterates: Buy | $59 | $36.26 | +62.71% | 13 | Dec 17, 2024 | |
| DARE Daré Bioscience | Reiterates: Buy | $12 | $2.71 | +342.80% | 16 | Dec 17, 2024 | |
| NMRA Neumora Therapeutics | Reiterates: Buy | $30 | $10.85 | +176.50% | 3 | Dec 16, 2024 | |
| XENE Xenon Pharmaceuticals | Reiterates: Buy | $53 | $38.63 | +37.20% | 3 | Dec 12, 2024 | |
| PRAX Praxis Precision Medicines | Reiterates: Buy | $120 | $76.52 | +56.82% | 21 | Dec 12, 2024 | |
| PTGX Protagonist Therapeutics | Reiterates: Buy | $50 | $41.49 | +20.51% | 25 | Dec 10, 2024 | |
| IRON Disc Medicine | Reiterates: Buy | $118 | $64.50 | +82.95% | 13 | Dec 9, 2024 | |
| CHRS Coherus BioSciences | Reiterates: Buy | $7 | $1.52 | +360.53% | 22 | Dec 4, 2024 | |
| OTLK Outlook Therapeutics | Reiterates: Buy | $30 | $1.44 | +1,983.33% | 14 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $617 | $623.82 | -1.09% | 32 | Nov 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $14 | $5.61 | +149.55% | 21 | Nov 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $2.38 | +950.42% | 22 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $3.39 | +430.97% | 11 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $2 | $0.23 | +769.57% | 19 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $11.57 | +55.57% | 16 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $69 → $81 | $53.60 | +51.12% | 22 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $6.6 | $3.09 | +113.59% | 19 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $14 | $4.39 | +218.91% | 14 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $51 | $25.86 | +97.22% | 19 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $27 | $10.89 | +147.93% | 23 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $4.47 | +78.97% | 9 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $83 → $57 | $33.21 | +71.64% | 23 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $2.16 | +131.48% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $37 | $29.71 | +24.54% | 22 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $0.65 | +669.23% | 8 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $15 | $9.59 | +56.41% | 13 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 | $1.11 | +800.90% | 5 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $23 → $10 | $15.52 | -35.57% | 7 | Dec 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $168 → $182 | $207.51 | -12.29% | 4 | Feb 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $19 | $4.68 | +300.64% | 2 | Jan 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $25 → $18 | $21.69 | -17.01% | 3 | Aug 29, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underweight | $8 | $22.09 | -63.78% | 7 | Jun 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $52 | $18.98 | +173.97% | 2 | Jun 11, 2019 |
Viridian Therapeutics
Dec 17, 2024
Reiterates: Buy
Price Target: $34
Current: $19.03
Upside: +78.67%
Biohaven
Dec 17, 2024
Reiterates: Buy
Price Target: $59
Current: $36.26
Upside: +62.71%
Daré Bioscience
Dec 17, 2024
Reiterates: Buy
Price Target: $12
Current: $2.71
Upside: +342.80%
Neumora Therapeutics
Dec 16, 2024
Reiterates: Buy
Price Target: $30
Current: $10.85
Upside: +176.50%
Xenon Pharmaceuticals
Dec 12, 2024
Reiterates: Buy
Price Target: $53
Current: $38.63
Upside: +37.20%
Praxis Precision Medicines
Dec 12, 2024
Reiterates: Buy
Price Target: $120
Current: $76.52
Upside: +56.82%
Protagonist Therapeutics
Dec 10, 2024
Reiterates: Buy
Price Target: $50
Current: $41.49
Upside: +20.51%
Disc Medicine
Dec 9, 2024
Reiterates: Buy
Price Target: $118
Current: $64.50
Upside: +82.95%
Coherus BioSciences
Dec 4, 2024
Reiterates: Buy
Price Target: $7
Current: $1.52
Upside: +360.53%
Outlook Therapeutics
Nov 29, 2024
Reiterates: Buy
Price Target: $30
Current: $1.44
Upside: +1,983.33%
Nov 20, 2024
Reiterates: Buy
Price Target: $617
Current: $623.82
Upside: -1.09%
Nov 20, 2024
Reiterates: Neutral
Price Target: $14
Current: $5.61
Upside: +149.55%
Nov 18, 2024
Reiterates: Buy
Price Target: $25
Current: $2.38
Upside: +950.42%
Nov 14, 2024
Reiterates: Buy
Price Target: $18
Current: $3.39
Upside: +430.97%
Nov 14, 2024
Reiterates: Neutral
Price Target: $2
Current: $0.23
Upside: +769.57%
Nov 13, 2024
Reiterates: Buy
Price Target: $18
Current: $11.57
Upside: +55.57%
Nov 13, 2024
Maintains: Buy
Price Target: $69 → $81
Current: $53.60
Upside: +51.12%
Nov 8, 2024
Reiterates: Neutral
Price Target: $6.6
Current: $3.09
Upside: +113.59%
Nov 8, 2024
Reiterates: Buy
Price Target: $14
Current: $4.39
Upside: +218.91%
Nov 8, 2024
Reiterates: Buy
Price Target: $51
Current: $25.86
Upside: +97.22%
Nov 7, 2024
Reiterates: Buy
Price Target: $27
Current: $10.89
Upside: +147.93%
Nov 7, 2024
Reiterates: Buy
Price Target: $8
Current: $4.47
Upside: +78.97%
Nov 6, 2024
Maintains: Buy
Price Target: $83 → $57
Current: $33.21
Upside: +71.64%
Nov 6, 2024
Reiterates: Neutral
Price Target: $5
Current: $2.16
Upside: +131.48%
Oct 25, 2024
Reiterates: Neutral
Price Target: $37
Current: $29.71
Upside: +24.54%
Oct 1, 2024
Reiterates: Buy
Price Target: $5
Current: $0.65
Upside: +669.23%
Sep 16, 2024
Reiterates: Buy
Price Target: $15
Current: $9.59
Upside: +56.41%
Jun 7, 2022
Downgrades: Neutral
Price Target: $10
Current: $1.11
Upside: +800.90%
Dec 9, 2021
Maintains: Neutral
Price Target: $23 → $10
Current: $15.52
Upside: -35.57%
Feb 20, 2020
Maintains: Equal-Weight
Price Target: $168 → $182
Current: $207.51
Upside: -12.29%
Jan 23, 2020
Downgrades: Neutral
Price Target: $19
Current: $4.68
Upside: +300.64%
Aug 29, 2019
Maintains: Underweight
Price Target: $25 → $18
Current: $21.69
Upside: -17.01%
Jun 11, 2019
Initiates: Underweight
Price Target: $8
Current: $22.09
Upside: -63.78%
Jun 11, 2019
Initiates: Overweight
Price Target: $52
Current: $18.98
Upside: +173.97%